Overall, the results from
oral kinase inhibitors are very exciting, says Robinson.
Not exact matches
An international research group has now shown that there is another, equally effective
oral treatment option: the combination of methotrexate and the chemically synthesised Janus
Kinase Inhibitor tofacitinib.
A class of
oral specialty drugs, tyrosine
kinase inhibitors (TKIs), has revolutionized the treatment of CML, largely transforming it into a chronic condition and enabling many patients to have a near - normal lifespan, particularly when compared to a median survival of less than three years with prior therapies.
Oral administration of Bruton's Tyrosine
Kinase (Btk)
inhibitors impairs GPVI - mediated platelet function.
Oral administration of Bruton's tyrosine
kinase inhibitors impairs GPVI - mediated platelet function.
The study tested a lower dose of the
oral multi-targeted tyrosine
kinase inhibitor sunitinib than in previous trials, where toxicity proved too much of a problem.
The US Food and Drug Administration (FDA) recently approved the
oral Bruton tyrosine
kinase (BTK)
inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.
Multi-center, placebo - controlled, double - blind, randomized study of
oral toceranib phosphate (SU11654), a receptor tyrosine
kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
Lectures provided: Recent advancements in Oncology;
Oral tumors; Canine Lymphoma, Tysosine
Kinase Inhibitors; Keystone Annual PVMA meeting, April 2014, Penn St, PA